News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

High compliance with Optune linked to greatest survival benefit for glioblastoma

Al's Comment:

 There is a dose response curve. (Which also should convince the naysayers that the device is effective)   The better the compliance, the better the patients do. They have been saying 75% is the target compliance rate but the new data shows that 90% should be the target.  Those patients who had a compliance rate of 90% or more, had a survival rate of 29.3% at 5 years, compared to the control group (temodar) which had a 4.5% survival rate, an almost 650% increase in survival rate.
   With a compliance of 70-80%, the 5 year survival rate drops to 19.9%.   Still much better than the control group... so don't stress too much if you can't hit the 90%, but try.


Posted on: 11/21/2017

High compliance with Optune linked to greatest survival benefit for glioblastoma

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740